Table 1 Various vaccine strategies targeting Survivin as vaccine antigen

Dendritic cell based adenoviral vector expressing full length human mutant Survivin

Significant antitumor effect against three different tumors EL-4 lymphoma, MC-38 carcinoma, and MethA sarcoma. Only partial protection against established tumours observed

[125]

Recombinant fowl pox virus encoding human Survivin

Anti-tumour effect in mouse model of mesothelioma, improved T cell response against tumour cells

[126]

Recombinant mouse Survivin and 4IBBL as adjuvant

Prime-boost vaccination strategy was effective in eradicating 3LL lung carcinoma in 100 % of mice

[127, 128]

Recombinant modified vaccinia Ankara (MVA) expressing full length mouse Survivin

Significant tumor regression and prolonged survival in murine model of pancreatic cancer

[129]

DNA vaccine encoding chemokine CCL21 and Survivin

Oral delivery of this vaccine using attenuated S. tymphimurium elicited activation of DCS and effective anti-Survivin CD8 T cells response in a murine model of pulmonary metastasis

[130]

HLA restricted Survivin peptide 2B 80–88

Phase I clinical trial in advanced urothelial patients, showed good CTL response and no adverse effects

[104]

Survivin 2B 80–88 and type I interferon

Clinical improvement in colon cancer patients

[131]

Survivin 2B peptide based vaccination

Clinical improvement in colorectal cancer/breast cancer

[107]

DPX-Survivac using HLA-I restricted Survivin epitopes

Effective anti-Survivin CTL response in ovarian cancer

Vaccine induced T cell activation against Survivin antigen

[111, 132]

Autologous dendritic cells pulsed with p53, Survivin and telomerase-derived peptides in combination with low-dose interleukin (IL)-2 and interferon (IFN)-alpha2b in phase I trial

Treatment-associated stable disease (SD) was observed in 24 % of malignant melanoma patients. SD correlated with prolonged survival suggesting a clinical benefit

[133]

EMD640744: a cocktail of five HLA class I-binding Survivin peptides in Montanide (^®) ISA 51 VG in phase I trial

T-cell responses against Survivin peptides in the majority of patients with solid cancers

[110]